Eflornithine topical - Bristol-Myers Squibb/Gillette

Drug Profile

Eflornithine topical - Bristol-Myers Squibb/Gillette

Alternative Names: BMS-203522; Eflornithine cream; Eflornithine HCl; Eflornithine hydrochloride topical; Vaniqa

Latest Information Update: 14 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb; Gillette
  • Developer Bristol-Myers Squibb; Clinuvel Pharmaceuticals; Stiefel Laboratories
  • Class Basic amino acids; Diamino amino acids; Small molecules
  • Mechanism of Action Enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hirsutism

Most Recent Events

  • 07 May 2015 Eflornithine topical licensed to Cipher Pharmaceuticals in Canada
  • 19 Dec 2012 SkinMedica has been acquired by Allergan
  • 22 Jul 2009 Stiefel Laboratories has been acquired by GlaxoSmithKline
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top